论文部分内容阅读
药物洗脱支架(DES)取代裸金属支架(BMS)应用于临床是心脏病介入治疗领域的突破性进展. DES的介入治疗可与冠状动脉旁路移植术(CABG)媲美,后者是目前临床上治疗冠状动脉疾病的标准方法. DES可较好控制再狭窄率的效果. 此外,复杂程度较低的冠心病患者用DES进行经皮冠状动脉介入(PCI)的疗效好. 但是CABG依然是左前降支或左主干冠状动脉病以及复杂的多血管病变患者优先选择的治疗方案.“,”Bare-metal stents have been replaced by drug-eluting stents( DES) , which is considered as a breakthrough therapy that might compete with coronary artery bypass grafting(CABG) as the standard treat-ment for coronary artery disease.DES can control the effect of restenosis rate.In addition,less complex coro-nary heart disease patients treated by percutaneous coronary intervention with DES have better therapeutic effect.However,CABG is still the priority option for patients with left anterior descending coronary artery involvement, left main involvement, or multivessel disease.